Biotest Aktiengesellschaft provided earnings guidance for the year 2021. For financial year 2021, the Board of Management expects sales growth in the mid-single-digit percentage range. Earnings in 2021 will be influenced by various factors. Besides the expected expenses of EUR 75 million to EUR 85 million from the Biotest Next Level expansion project, including the associated research and development costs the tense situation in the crisis regions, particularly in the Middle East and Asia, as well as the global impact of the COVID-19 pandemic, could also have an impact. Based on the aforementioned factors, the Board of Management expects LBIT to be between EUR 5 million and EUR 10 million. For EBIT adjusted for the impact on earnings of the Biotest Next Level project, the Board of Management anticipates an amount between EUR 65 million and EUR 80 million.